Immunohistochemistry Panel (5-IHC) at Lahore PCR Lab

Immunohistochemistry Panel (5-IHC) at Lahore PCR Lab

Immunohistochemistry (IHC) is an indispensable diagnostic modality in modern pathology that combines anatomical, immunological, and biochemical techniques to image specific cellular components. The Immunohistochemistry Panel (5-IHC) at Lahore PCR Lab is a specialized diagnostic profile utilizing five distinct monoclonal or polyclonal antibodies to identify specific antigens within a tissue sample. This panel is crucial in clinical oncology and surgical pathology for characterizing tumors of uncertain origin, determining prognostic indicators, and identifying therapeutic targets.

By applying these five highly specific antibodies to thin sections of tissue biopsies or surgical resections, pathologists can visualize the precise localization of proteins within cells (nuclear, cytoplasmic, or membranous). This cellular-level visualization is achieved through an enzymatic reaction that produces a colored pigment (chromogen) visible under a light microscope. The 5-IHC panel is particularly valuable when standard Hematoxylin and Eosin (H&E) staining is insufficient to provide a definitive diagnosis, such as in poorly differentiated neoplasms, metastatic tumors of unknown primary origin, or complex lymphoid proliferations.

At Lahore PCR Lab in Lahore, Pakistan, this panel is executed using state-of-the-art automated staining platforms and interpreted by highly experienced consultant pathologists. The clinical utility of the 5-IHC panel spans across multiple organ systems, including the breast, lungs, gastrointestinal tract, prostate, gynecological tract, and lymphatic system. It provides critical diagnostic clarity, allowing oncologists to design highly personalized, targeted treatment regimens for patients.

Clinical Procedure: What to Expect

Patient Preparation

• Submission of Tissue Blocks: If the biopsy or surgical resection was performed at another facility, patients or their relatives must obtain the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block along with the corresponding Hematoxylin and Eosin (H&E) stained slides and the original histopathology report. Ensure these are transported in a cool, dry container to prevent melting or degradation of the paraffin wax.
• Biopsy Coordination: If the biopsy is to be performed, follow the specific clinical guidelines provided by your interventional radiologist or surgeon. This may include fasting for 6 to 8 hours (for core needle biopsies of abdominal organs) or temporarily discontinuing blood-thinning medications (such as aspirin, clopidogrel, or warfarin) under medical supervision.
• Clinical History Documentation: Provide a complete clinical history, including previous pathology reports, imaging scans (CT, MRI, or PET scans), current cancer staging, and details of any prior chemotherapy, radiotherapy, or immunotherapy. This clinical context is vital for the pathologist to select the most appropriate five antibodies for the panel.
• Consent and Administrative Forms: Complete all necessary consent forms and laboratory requisition sheets at Lahore PCR Lab, ensuring the patient's identity and sample details match perfectly.

During the Procedure

The laboratory process begins with specimen reception and accessioning, where the tissue block is received at Lahore PCR Lab and assigned a unique laboratory identification number to ensure absolute traceability. A skilled histotechnologist uses a high-precision microtome to cut extremely thin sections (typically 3 to 5 micrometers thick) from the paraffin block. These sections are carefully mounted onto specialized, positively charged glass slides to ensure tissue adhesion during subsequent chemical treatments.

The slides are then heated and treated with organic solvents (such as xylene) to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue sections. Because the formalin fixation process creates cross-links that can mask target antigens, the slides undergo heat-induced epitope retrieval (HIER) using specialized buffers in a pressure cooker or microwave, or enzymatic epitope retrieval (EER) to unmask the target proteins.

The five selected primary antibodies are applied to individual slides. The slides are incubated under controlled temperature and humidity to allow highly specific antigen-antibody binding. A secondary antibody conjugated with an enzyme (such as Horseradish Peroxidase or Alkaline Phosphatase) is applied, followed by a chromogenic substrate (such as Diaminobenzidine – DAB). This reaction produces a visible brown or red precipitate at the site of antigen expression. The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, and sealed with a coverslip. Finally, a consultant pathologist examines the slides under a high-resolution light microscope, evaluating the percentage of positive cells, intensity of staining, and subcellular localization for each of the five markers.

When is an Immunohistochemistry Panel (5-IHC) Performed?

Breast Cancer Subtyping and Prognostication

The 5-IHC panel is routinely performed on breast biopsy specimens to determine the molecular subtype of breast carcinoma. This panel typically includes Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2), Ki-67 (proliferation marker), and an epithelial marker like Cytokeratin or a basal marker like CK5/6. Evaluating these five markers is critical because it directly dictates the therapeutic strategy. For instance, hormone receptor-positive tumors are candidates for endocrine therapy, HER2-positive tumors require targeted anti-HER2 therapy (such as trastuzumab), and triple-negative breast cancers (negative for ER, PR, and HER2) are managed with chemotherapy and immunotherapy. The Ki-67 index provides essential prognostic information regarding tumor proliferation and aggressiveness.

Identifying Carcinoma of Unknown Primary (CUP)

When a patient presents with metastatic disease (e.g., tumors in the liver, lungs, or bones) without an obvious primary tumor site, a 5-IHC panel is utilized to determine the tissue of origin. Pathologists select a panel of five lineage-specific markers, such as Cytokeratin 7 (CK7), Cytokeratin 20 (CK20), Thyroid Transcription Factor-1 (TTF-1), CDX2, and GATA3. The specific staining pattern (e.g., CK7+/CK20-/TTF-1+ indicates lung adenocarcinoma, while CK7-/CK20+/CDX2+ indicates colorectal adenocarcinoma) helps narrow down the primary site. Identifying the primary tumor is critical because oncological treatments are highly site-specific, and treating a metastatic cancer with the correct organ-specific protocol significantly improves patient survival rates.

Differentiating Benign from Malignant Lesions

In challenging diagnostic cases, such as atypical intraductal lesions of the breast or atypical small acinar proliferations in the prostate, standard morphological evaluation may not be definitive. A 5-IHC panel can be designed to distinguish benign lesions from invasive malignancies. For prostate biopsies, a panel consisting of p63, High Molecular Weight Cytokeratin (34betaE12), and AMACR (Alpha-Methylacyl-CoA Racemase) is commonly used. The absence of basal cell markers (p63 and HMW-CK) combined with the strong expression of the oncogenic marker AMACR confirms a diagnosis of invasive prostate adenocarcinoma, preventing both underdiagnosis of cancer and unnecessary over-treatment of benign mimics.

Lymphoma Classification and Characterization

Lymphoproliferative disorders present highly complex morphological features that overlap significantly. A 5-IHC panel is essential to classify lymphomas into specific lineages and subtypes. A typical initial panel may include CD3 (T-cell marker), CD20 (B-cell marker), CD30, CD15, and Ki-67. This combination allows pathologists to differentiate between B-cell and T-cell non-Hodgkin lymphomas, or identify classic Hodgkin lymphoma (characterized by CD30+ and CD15+ Reed-Sternberg cells). Accurate classification is paramount, as the chemotherapy regimens, targeted monoclonal antibody therapies (like rituximab), and overall prognoses vary drastically between different lymphoma subtypes.

Guiding Targeted Oncological Therapy and Immunotherapy

Modern oncology relies heavily on personalized medicine, where treatment is tailored to the genetic and molecular profile of the tumor. The 5-IHC panel is increasingly used to assess the expression of therapeutic targets and immune checkpoint proteins. This panel may include markers like PD-L1 (Programmed Death-Ligand 1), mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) to assess microsatellite instability (MSI), and specific mutated proteins like BRAF V600E. High PD-L1 expression indicates a high likelihood of response to immune checkpoint inhibitors (such as pembrolizumab), while mismatch repair deficiency guides both hereditary screening (Lynch syndrome) and eligibility for immunotherapy across various solid tumors.

What Does an Immunohistochemistry Panel (5-IHC) Detect?

• Nuclear expression of Estrogen Receptor (ER) in breast epithelial cells.
• Nuclear expression of Progesterone Receptor (PR) indicating hormone responsiveness.
• Membranous circumferential staining of HER2/neu protein in breast or gastric carcinomas.
• Ki-67 nuclear staining percentage, indicating the active proliferative fraction of the tumor.
• Cytoplasmic expression of Cytokeratin 7 (CK7) in glandular epithelial cells.
• Cytoplasmic expression of Cytokeratin 20 (CK20) in gastrointestinal epithelial cells.
• Nuclear expression of Thyroid Transcription Factor-1 (TTF-1) in lung or thyroid neoplasms.
• Nuclear expression of CDX2, confirming gastrointestinal (colorectal) differentiation.
• Membranous expression of CD20, confirming B-lymphocyte lineage.
• Membranous expression of CD3, confirming T-lymphocyte lineage.
• Membranous and Golgi-zone staining of CD30 in Reed-Sternberg cells.
• Membranous and cytoplasmic expression of CD15 in Hodgkin lymphoma cells.
• Nuclear accumulation of mutated p53 tumor suppressor protein (or complete null phenotype).
• Nuclear expression of p63 in basal cells of the prostate, breast, or squamous epithelium.
• Nuclear expression of p40, confirming squamous cell carcinoma of the lung.
• Cytoplasmic expression of Synaptophysin in neuroendocrine tumors.
• Cytoplasmic expression of Chromogranin A in neuroendocrine cells.
• Cytoplasmic and membranous expression of CD117 (c-KIT) in gastrointestinal stromal tumors (GIST).
• Nuclear expression of GATA3 in urothelial and luminal breast carcinomas.
• Nuclear expression of PAX8 in renal cell, thyroid, or Mullerian (ovarian/endometrial) carcinomas.
• Cytoplasmic expression of Prostate-Specific Antigen (PSA) in prostatic tissue.
• Cytoplasmic and nuclear expression of S100 protein in melanocytic and neural crest tumors.
• Cytoplasmic expression of Melan-A (Mart-1) in malignant melanoma.
• Cytoplasmic expression of Vimentin in mesenchymal cells and sarcomas.
• Membranous expression of E-cadherin, distinguishing ductal (positive) from lobular (negative) breast carcinoma.

Turnaround Time and Report Access at Lahore PCR Lab

The Immunohistochemistry Panel (5-IHC) is a highly complex, multi-step diagnostic procedure that requires meticulous laboratory processing and expert pathological evaluation. At Lahore PCR Lab, located in Lahore, Pakistan, the turnaround time for a 5-IHC panel typically ranges from 5 to 7 working days. This timeframe ensures that tissue sections undergo optimal antigen retrieval, precise antibody incubation, and rigorous quality control checks to prevent false-positive or false-negative results.

Once the slides are stained, they are reviewed by a team of consultant pathologists who correlate the IHC staining patterns with the patient's clinical history and morphological findings on H&E slides. Patients and referring oncologists can access diagnostic reports through Lahore PCR Lab's secure online portal. An automated SMS notification is sent to the patient's registered mobile number as soon as the report is verified and signed off. Physical copies of the reports, complete with high-resolution photomicrographs of the stained slides when clinically indicated, can be collected directly from the main laboratory or designated collection centers across Lahore.

Immunohistochemistry Panel (5-IHC) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Estrogen & Progesterone Receptors (ER/PR)	Negative nuclear staining in non-target tissues; normal physiological expression in benign breast lobules.	Strong nuclear expression in luminal breast adenocarcinoma; loss of expression in triple-negative breast cancers.
HER2/neu Protein Expression	Absent or faint, incomplete membranous staining (Score 0 or 1+) in normal epithelial cells.	Strong, complete, circumferential membranous staining (Score 3+) indicating gene amplification and therapeutic targetability.
Ki-67 Proliferation Index	Low nuclear staining (typically < 5%) in resting, non-dividing normal tissues.	Elevated nuclear staining (e.g., > 30% to 90%) indicating highly proliferative, aggressive malignancies like Burkitt lymphoma or high-grade carcinomas.
Cytokeratin 7 / Cytokeratin 20 (CK7/CK20)	Specific localized expression matching tissue of origin (e.g., lung CK7+/CK20-; colon CK7-/CK20-).	Altered or discordant expression profiles (e.g., CK7+/CK20+ in pancreaticobiliary carcinomas) helping identify primary tumor sites.
Basal Cell Markers (p63 / HMW-CK)	Continuous, intact basal cell layer lining benign prostatic acini or breast ducts.	Complete absence of the basal cell layer in invasive prostatic adenocarcinoma or invasive ductal carcinoma of the breast.
Lymphoid Lineage Markers (CD3 / CD20)	Balanced distribution of T-cells (CD3+) and B-cells (CD20+) within normal lymphoid architecture (follicles and paracortex).	Monoclonal expansion of either CD20+ B-cells or CD3+ T-cells, destroying normal lymph node architecture, indicating lymphoma.
Neuroendocrine Markers (Synaptophysin / Chromogranin)	Restricted expression in normal endocrine organs and diffuse neuroendocrine cells.	Diffuse, intense cytoplasmic positivity in neuroendocrine tumors (NETs), small cell carcinomas, or carcinoid tumors.
Lineage-Specific Transcription Factors (TTF-1 / CDX2 / PAX8)	Expression confined to respective normal organs (TTF-1 in lung/thyroid; CDX2 in colon; PAX8 in kidney/gynecological tract).	Strong nuclear expression in metastatic lesions, confirming the primary origin (e.g., TTF-1 positivity in a brain lesion confirms metastatic lung cancer).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Immunohistochemistry Panel (5-IHC)?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified, fellowship-trained consultant pathologists specializing in histopathology and molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort and convenience, offering clear guidance on sample submission and prompt communication throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring high reproducibility and accuracy of all immunohistochemical stains.
• Professional Reporting: Reports are comprehensive, featuring detailed semi-quantitative scoring (e.g., Allred score for ER/PR, ASCO/CAP guidelines for HER2) and clinical correlations.
• Modern Diagnostic Approach: We utilize state-of-the-art automated IHC staining platforms that minimize manual errors and ensure consistent staining quality.
• Comfortable Environment: Our collection centers and main laboratory in Lahore offer a professional, clean, and welcoming environment for patients and their families.
• Convenient Location: Strategically located in Lahore, Pakistan, making it easily accessible for patients from all parts of the city and surrounding regions.
• Commitment to Accurate Diagnosis: We understand the critical role of IHC in cancer management and are dedicated to providing timely, precise results to guide life-saving therapies.